Similar articles

• [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].

  Duan JC, An TT, Wu MN, Yang L, Bai H, Wang ZJ, Wang YY, Zhuo ML, Zhao J, Wang SH, Wang J. Duan JC, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):323-8. Zhonghua Jie He He Hu Xi Za Zhi. 2012. PMID: 22883988 Chinese.
• [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].

  Cobo M, Gutiérrez V, Rodelo L, López O, Ruiz M, Godoy A. Cobo M, et al. Med Clin (Barc). 2016 Apr;146 Suppl 1:25-9. doi: 10.1016/S0025-7753(16)30260-3. Med Clin (Barc). 2016. PMID: 27426245 Review. Spanish.
• Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.

  Kuiper JL, Ronden MI, Becker A, Heideman DA, van Hengel P, Ylstra B, Thunnissen E, Smit EF. Kuiper JL, et al. J Clin Pathol. 2015 Apr;68(4):320-1. doi: 10.1136/jclinpath-2015-202866. Epub 2015 Feb 6. J Clin Pathol. 2015. PMID: 25661795 No abstract available.
• Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

  Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
• Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.

  Saba NF, Khuri FR, Shin DM. Saba NF, et al. Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim. Oncology (Williston Park). 2006. PMID: 16562649 Review.